In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...

Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

The stock's fall snapped a four-day winning streak.

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

The court has ruled that restricting Young Poong's voting rights at Korea Zinc's extraordinary shareholders' meeting on January 23 was unlawful, suspending the effectiveness of most resolutions passed ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...

Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. Incyte ( NASDAQ:INCY – Get Free Report ) last released its earnings results on Monday, February 10th.

"We have to be very careful about how we use state money for business going forward," says Matt Meyer, Delaware's new governor, who is a former school teacher and corporate lawyer.